Purpose: Central precocious puberty (CPP) is less common in boys than girls; very little data is reported on effect of gonadotropin-releasing hormone analog (GnRHa) treatment in boys with CPP. The aim of the study was to evaluate growth changes in boys with CPP and early puberty (EP) treated with GnRHa therapy for 1 year.
Subjects and Methods: In 60 (39 CPP and 21 EP) boys with confirmed diagnosis of CPP and EP, auxological (height, height standard deviation score (HtSDS), bone age (BA), Ht prediction) and endocrinological parameters were obtained at baseline, at 6 months, and at 1 year after GnRHa treatment in boys with CPP and EP. Pubertal progression ceased in all patients.
Results: During the treatment a decline in Ht SDS and growth velocity, LH, FSH and testosterone levels were observed (P<0.01); and a deceleration in the maturation of bones after 1year GnRHa treatment was observed (P=0.000). Predicted adult height (PAH) SDS was increased during treatment with GnRHa (P<0.01). There was no difference in the auxological and endocrinological parameters after 1 year treatment between CPP and EP. There was significant difference in PAH SDS between organic CPP and non-organic CPP (P<0.05).
Conclusion: The present data indicate that GnRHa therapy significantly improves growth prognosis in boys with CPP and EP. Boys with organic forms might have poorer height prognosis.
27 - 29 Sep 2018
European Society for Paediatric Endocrinology